文献速递临床生化临床血液与体液

新生儿维生素B12缺乏:对个体健康状况和医疗成本的影响

Vitamin B12 deficiency in newborns: impact on individual's health status and healthcare costs.
PubMed 文献 · Clin Chem Lab Med · 2024-10-03

基于146,470名筛查新生儿中识别的87例经生物标志物确认的营养性B12缺乏(母源性),基线中位血清B12为185.0 ng/L、血浆Hcy升高三倍;肌注B12后首次随访血清B12升高五倍、Hcy恢复正常;诊断和管理所有B12缺乏新生儿的成本为188,480 €/年。

要点

  • 新生儿B12缺乏可通过新生儿筛查生物标志物识别并经血清B12和血浆Hcy确认。
  • 肌注B12补充后血清B12升高五倍、Hcy恢复正常。
  • 诊断和管理所有B12缺乏新生儿的医疗成本为188,480 €/年。

核心结论

  • 预防新生儿B12耗竭可降低医疗成本并可能改善健康结局,但仍需进一步研究确定孕妇边缘性及低B12状态的临床路径。

研究设计与样本

  • 连续病例系列研究,从146,470名筛查新生儿中识别87名B12代谢生物标志物异常者,并对新生儿及母亲检测血清B12和血浆Hcy以确认母源性营养性B12缺乏,同时进行成本分析。

主要发现

  • 基线中位(四分位距)血清B12为185.0(142.3-246.0)ng/L,血浆Hcy浓度升高至正常水平三倍以上,确认新生儿严重缺乏。
  • 肌注B12补充后首次随访血清B12升高五倍,Hcy水平恢复正常。
  • 从医疗保健角度,诊断和管理所有B12缺乏新生儿的成本为188,480 €/年。

关键数值与推荐

  • 新生儿B12缺乏确认依据:血清B12中位185.0(142.3-246.0)ng/L及血浆Hcy升高至正常三倍以上。
  • 肌注B12补充后首次随访血清B12升高五倍、Hcy恢复正常。
  • 诊断和管理所有B12缺乏新生儿的成本为188,480 €/年。

临床怎么用

  • 对新生儿筛查提示B12代谢生物标志物异常者,应检测新生儿及母亲血清B12和血浆Hcy以确认母源性营养性B12缺乏。
  • 确诊后予肌注B12补充,并在随访中监测血清B12和血浆Hcy以评估治疗反应。

局限性

  • 需进一步研究确定识别、治疗和监测孕妇边缘性及低B12状态的临床路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The identification of vitamin B12 (B12) deficiency in the newborn may prevent neurological damage and a delay in the normal growth. In this study we characterized the incidence of B12 deficiency in newborns, the costs associated to the clinical diagnosis and management, and the relevance to optimize the use of cobalamin biomarkers during treatment follow-up. METHODS: Starting from a continuous case series of 146,470 screened newborns (November, 1st 2021- December, 3rd 2023), the Regional Reference Laboratory for Neonatal Screening identified 87 newborns having altered levels of biomarkers of cobalamin metabolism measured by newborn screening. These subjects were confirmed with a nutritional B12 deficiency of maternal origin by performing the serum B12 measurements and plasma homocysteine (Hcy) both on the newborns and respective mothers. A cost analysis was performed to characterize the costs/year of identifying and managing B12 deficiency cases. RESULTS: At baseline, median (interquartile range) serum B12 levels of 185.0 (142.3-246.0) ng/L and threefold increased plasma Hcy concentrations above the normal level confirmed a severe condition of deficiency in the newborns. After intramuscular B12 supplementation, serum B12 measured at the first follow up visit showed a fivefold increase, and the levels of Hcy returned to normal. From the healthcare perspective, the costs for diagnosing and managing all newborns with B12 deficiency is 188,480 €/year. CONCLUSIONS: Preventing B12 depletion in newborns lowers healthcare costs and likely improves their health outcomes. Further studies are however required to address the clinical pathway to identify, treat and monitor pregnant women with marginal and low B12 status, in order to achieve these goals.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Ferraro S, Lucchi S, Montanari C, et al. Vitamin B12 deficiency in newborns: impact on individual's health status and healthcare costs. Clin Chem Lab Med. 2024. PMID: 39356629. doi:10.1515/cclm-2024-0692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。